Shigella flexneri and Bacillary Dysentery

Shigella flexneri belongs to the family Enterobacteriaceae and the genus Shigella. It is a Gram-negative, non-motile, rod-shaped bacterium. The organism does not produce spores and lacks flagella, which distinguishes it from several other enteric bacteria such as Salmonella.

The bacterium is facultatively anaerobic and can grow on standard laboratory culture media. Colonies typically appear smooth, translucent, and moderately sized on agar plates. Within the genus Shigella, species are classified into four major serogroups (A–D) based on antigenic structure. Group B, represented by S. flexneri, has historically been the predominant circulating serogroup in many regions and includes multiple serotypes.

The pathogenicity of Shigella flexneri depends primarily on its ability to invade intestinal epithelial cells and trigger inflammatory damage to the colonic mucosa.

Infection begins when bacteria adhere to epithelial cells in the distal small intestine and colon. Through specialized virulence factors encoded on invasion plasmids, the organism induces uptake by host cells and replicates intracellularly. It subsequently spreads from cell to cell, leading to localized tissue destruction and inflammatory ulceration.

A critical feature of S. flexneri infection is its extremely low infectious dose. Ingestion of as few as 10–100 viable bacterial cells may be sufficient to cause disease.

The organism also produces endotoxin, which contributes to systemic symptoms such as fever and toxemia. Endotoxin-mediated inflammation in the intestinal mucosa is responsible for the characteristic mucous and bloody diarrhea observed in dysentery.

The incubation period for S. flexneri infection typically ranges from one to three days. Clinical manifestations vary in severity depending on host factors and bacterial virulence.

• Acute bacillary dysentery: The most common presentation. Symptoms include sudden fever, abdominal cramps, diarrhea that rapidly progresses to mucous or bloody stools, and pronounced tenesmus.
• Toxic dysentery: A severe form more frequently observed in young children. It may present with high fever, shock, convulsions, or altered consciousness, sometimes before obvious gastrointestinal symptoms appear.
• Chronic dysentery: Persistent infection lasting longer than two months may develop when initial treatment is incomplete or host immunity is compromised. Patients may experience recurrent gastrointestinal symptoms or become asymptomatic carriers.

Diagnosis relies on clinical symptoms combined with laboratory investigation. Microscopic examination of stool specimens often reveals abundant leukocytes, erythrocytes, and macrophages.

Definitive diagnosis requires isolation of Shigella from stool culture. However, molecular diagnostic methods have become increasingly important due to their speed and sensitivity.

Probe-based real-time PCR assays targeting species-specific genetic markers enable rapid detection of Shigella flexneri in stool or environmental samples.

Management of shigellosis involves antimicrobial therapy and supportive care. Early treatment can shorten disease duration and reduce transmission.

Increasing antimicrobial resistance among Shigella strains presents a growing challenge. Selection of appropriate therapy should therefore be guided by regional resistance surveillance or antimicrobial susceptibility testing whenever possible.

Shigella flexneri remains a major cause of bacillary dysentery worldwide. Its low infectious dose, efficient person-to-person transmission, and capacity for antimicrobial resistance make it a persistent public health concern.

Improved sanitation, safe water supplies, and effective hygiene practices are essential for prevention. In parallel, advances in molecular diagnostic methods support rapid pathogen identification and improved epidemiological surveillance.